FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Evaluates Peptides for Section 503A Compounding List Lance Liberti, MBA, BCPA posted on the topic LinkedIn HHS Peptides Move: Compounding Pharmacy Concerns Scott Brunner, CAE posted on the topic LinkedIn FDA considers adding a dozen peptides to its bulk drug compounding list RAPS